Videos

Shay Rajavel, MS3, shares details on an AUA 2025 presentation on CO2 gas embolism during laparoscopic surgery.

Kevin C. Zorn, MD, FRCSC, FACS, recaps the AUA 2025 session, “State-of-the-Art Lecture: Preservation of Ejaculatory Function with BPH Treatments."

Neal D. Shore, MD, FACS, shares the background and key findings from the phase 3 CREST trial, exploring sasanlimab plus BCG for BCG-naive NMIBC.

Vitaly Margulis, MD, shares his insights on initial data from the phase 3 ENLIGHTED trial.

Panelist discusses how clinical data from multiple studies demonstrate that aqua ablation therapy offers efficacy comparable with that of transurethral resection of the prostate (TURP) while providing superior safety, functionality, and durability benefits.

Joseph Jacob, MD, outlines key findings on TAR-200 monotherapy from cohort 2 of the SunRISe-1 study.

"The decision for which laser to use in your institution should be left up to the urologist and the hospital system," says Margaret A. Knoedler, MD.

A panelist discusses how clinicians should weigh the decision between enzalutamide and darolutamide for patients with metastatic hormone-sensitive prostate cancer (mHSPC) by considering each drug’s efficacy profile alongside their distinct adverse effect patterns, particularly darolutamide’s favorable central nervous system (CNS) toxicity profile vs enzalutamide’s more established long-term data, while also factoring in individual patient characteristics such as age, comorbidities, and potential drug interactions.

A panelist discusses how enzalutamide and darolutamide differ in their molecular structures and pharmacokinetic profiles, with darolutamide showing lower blood-brain barrier penetration, which potentially contributes to its reduced central nervous system adverse effects compared with enzalutamide.

“Oftentimes, [during] the very first visit, we are talking a lot. I am learning what's going on with them," says Anna Myers, CNP.

Matthew D. Galsky, MD, discusses how urologists should approach patient selection for perioperative durvalumab plus chemotherapy based on eligibility criteria for the NIAGARA trial.

The PRELUDE trial is assessing oncological outcomes with neoadjuvant 177Lu-PSMA-617 in high-risk, localized prostate cancer.

The use of onabotulinumtoxinA (onabotA, Botox) for the treatment of overactive bladder comes with several important considerations.

“Like any disease state, you want to make sure you have the right diagnosis; otherwise, you're not going to have a successful treatment plan," says Karyn S. Eilber, MD.

“We have to understand as providers that we're not going to be the one and only conduit for this information anymore, which is a good thing, to be honest," says Ian Metzler, MD, MTM.

Panelist discusses how patient outcomes have evolved over time with different benign prostatic hyperplasia (BPH) treatments, highlighting improvements in ejaculation preservation, durability, and post procedure complications across various techniques.

The website is meant to educate patients and their caregivers on several aspects of the kidney cancer journey.

“You absolutely need to have a CT scan prior to the surgery to best identify and really intimately understand the kidney’s anatomy," says Perry Xu, MD.

Merrill discusses the evolving non–muscle invasive bladder cancer treatment space.

There is also a need to improve multidisciplinary care, according to Ekene Enemchukwu, MD.

A panelist discusses how both the ARCHES and ARANOTE trials demonstrated significant improvements in radiographic progression-free survival with their respective novel hormonal therapies (enzalutamide in ARCHES and apalutamide in ARANOTE) when added to androgen deprivation therapy (ADT) for metastatic hormone-sensitive prostate cancer, with consistent benefits observed across key subgroups and generally manageable safety profiles.

A panelist discusses how the ARCHES and ARANOTE trials differ in their fundamental design elements, with ARCHES evaluating enzalutamide plus androgen deprivation therapy (ADT) vs placebo plus ADT in both metastatic and nonmetastatic patients, whereas ARANOTE specifically studied darolutamide and ADT vs ADT alone in patients with newly diagnosed metastatic hormone-sensitive prostate cancer.

“I think the great thing about Cost Plus Drugs is that, as we mentioned, it's simple, but it's also price transparent," says Raymond Xu, MD.

Enzalutamide plus talazoparib significantly extended overall survival vs enzalutamide alone in mCRPC.

Experts share their concluding thoughts on the recent progress and future outlook for the treatment of non–muscle-invasive bladder cancer (NMIBC).